Clinical outcome and management of XXXX .

@entity1 @entity1695 @entity3041 @entity158 @entity293 @entity810 @entity356
BACKGROUND: The clinical outcome of @entity356 remains unclear. The present study was designed to evaluate the clinical outcome and predictive factors of survival in @entity1 with @entity356 . METHODS: Twenty-five consecutive @entity1 with @entity356 between January 1998 and December 2007 were retrospectively analyzed. All @entity1 had @entity3041 ; 13 @entity1 had bilateral @entity3041 , and 12 @entity1 had unilateral @entity3041 . RESULTS: Ten @entity1 presented with @entity158 , 3 @entity1 with @entity293 , and 2 @entity1 with @entity810 . Seven (58%) of 12 @entity1 with unilateral @entity1695 experienced progression to bilateral @entity1695 during the follow-up period. Eighteen @entity1 (61%) were eventually managed with urinary diversion. In total, 5 @entity1 were managed with percutaneous nephrostomy, and 15 @entity1 with retrograde ureteral stenting. All symptomatic @entity1 responded to urinary diversion. The overall median survival was 5.8 months, and the 6-month and 1-year survival rates were 48 and 32%, respectively. Chemotherapy was found to be the only independent predictor of survival (p=0.0498). Median survival in @entity1 who received chemotherapy was 11.2 months, in comparison to 3.1 months in @entity1 who did not receive chemotherapy (p=0.0002). CONCLUSIONS: The prognosis of @entity356 was extremely poor, particularly when chemotherapy was not administered. The indications for palliative urinary diversion should be determined after considering the @entity1 's symptoms, the expected survival time, the possibility of further chemotherapeutic options, and the current quality of life.
